Original articleAdult cardiacDe Novo Aortic Regurgitation After Continuous-Flow Left Ventricular Assist Device Implantation
Section snippets
Material and Methods
The Institutional Review Board at our center approved this study and waived the need for individual patient consent.
Results
Median duration of LVAD support was 527 (289, 907; range, 60 to 2,433 days). Mild AR developed in 48 patients (51.6%) over a median duration of 126 days, progressing to moderate AR in 13 (14%) in 493 days and to severe AR in 2 (2.1%) by 1,231 days. Preoperative demographic and baseline characteristics of non-AR and AR groups are presented in Table 1. Patients in the AR group were significantly older, with mean age of 46.2 ± 11.9 years vs 39.9 ± 14.1 years in the non-AR group (p = 0.022). Other
Comment
The principal finding of this study was that the freedom from de novo moderate or greater AR after cf-LVAD implantation decreased sharply after 3 years. Clinical implications of these data may warrant consideration of prophylactic AoV replacement at the time of cf-LVAD implantation, particularly in patients with expected longer duration of support and in patients with preexisting AR that is more than mild.
References (14)
- et al.
Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients
J Heart Lung Transplant
(2013) - et al.
Aortic regurgitation during left ventricular assist device support
J Heart Lung Transplant
(2007) - et al.
Late aortic insufficiency related to poor prognosis during left ventricular assist device support
Ann Thorac Surg
(2011) - et al.
Monitoring of aortic valve opening and systolic aortic insufficiency in optimization of continuous-flow left ventricular assist device settings
J Cardiothorac Vasc Anesth
(2012) - et al.
Insufficiency of the native aortic valve and left ventricular assist system inflow valve after support with an implantable left ventricular assist system: signs, symptoms, and concerns
J Thorac Cardiovasc Surg
(2001) - et al.
Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation
J Thorac Cardiovasc Surg
(2013) - et al.
Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices
J Heart Lung Transplant
(2010)
Cited by (44)
Point-of-Care Ultrasound in the Evaluation of Patients with Left Ventricular Assist Devices at the Emergency Department
2022, Journal of Emergency MedicineCitation Excerpt :The aortic valve can close fully when LVAD is functioning normally. However, the aortic valve can degenerate over time and fuse at the commissures of the midpoint of leaflets, leading to aortic regurgitation in > 90% of patients (25). This, in turn, causes ineffective functioning of LVAD.
Aortic Insufficiency After Left Ventricular Assist Device Implantation: Predictors and Outcomes
2020, Annals of Thoracic SurgeryContinuous-Flow Left Ventricular Assist Devices and Valvular Heart Disease: A Comprehensive Review
2020, Canadian Journal of CardiologyCitation Excerpt :Aortic insufficiency is now a well documented time-related complication in patients supported with long-term CF-LVAD. From 15% to 52% of patients supported with a CF-LVAD develop significant AI by 1-2 years.7-22 A recent analysis from INTERMACS showed that more than 50% of CF-LVAD patients had mild AI after 2 years of support.
Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device–Induced Aortic Insufficiency
2018, Journal of Cardiothoracic and Vascular AnesthesiaThe Jarvik 2000 left ventricular assist device as a bridge to transplantation: Japanese Registry for Mechanically Assisted Circulatory Support
2018, Journal of Heart and Lung TransplantationCitation Excerpt :This may be a reflection of the overall low incidence of device malfunction across all types of implantable LVADs. AR is known to occur and progress after continuous-flow LVAD implantation, and the current literature provides evidence of the prophylactic effect of aortic valve opening against AR progression.3–6 The Jarvik 2000 with its ILS technology, which facilitates intermittent opening of the aortic valve, thus offers the prospect of minimizing AR progression; however, there is only a paucity of clinical studies having addressed this effect.2,7
A Complex Heart Team's Approach to a Patient With Giant Cell Myocarditis
2017, Canadian Journal of Cardiology